Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
α–Intercalated cells defend the urinary system from bacterial infection
Neal Paragas, … , Adam J. Ratner, Jonathan Barasch
Neal Paragas, … , Adam J. Ratner, Jonathan Barasch
Published June 17, 2014
Citation Information: J Clin Invest. 2014;124(7):2963-2976. https://doi.org/10.1172/JCI71630.
View: Text | PDF | Erratum
Research Article

α–Intercalated cells defend the urinary system from bacterial infection

  • Text
  • PDF
Abstract

α–Intercalated cells (A-ICs) within the collecting duct of the kidney are critical for acid-base homeostasis. Here, we have shown that A-ICs also serve as both sentinels and effectors in the defense against urinary infections. In a murine urinary tract infection model, A-ICs bound uropathogenic E. coli and responded by acidifying the urine and secreting the bacteriostatic protein lipocalin 2 (LCN2; also known as NGAL). A-IC–dependent LCN2 secretion required TLR4, as mice expressing an LPS-insensitive form of TLR4 expressed reduced levels of LCN2. The presence of LCN2 in urine was both necessary and sufficient to control the urinary tract infection through iron sequestration, even in the harsh condition of urine acidification. In mice lacking A-ICs, both urinary LCN2 and urinary acidification were reduced, and consequently bacterial clearance was limited. Together these results indicate that A-ICs, which are known to regulate acid-base metabolism, are also critical for urinary defense against pathogenic bacteria. They respond to both cystitis and pyelonephritis by delivering bacteriostatic chemical agents to the lower urinary system.

Authors

Neal Paragas, Ritwij Kulkarni, Max Werth, Kai M. Schmidt-Ott, Catherine Forster, Rong Deng, Qingyin Zhang, Eugenia Singer, Alexander D. Klose, Tian Huai Shen, Kevin P. Francis, Sunetra Ray, Soundarapandian Vijayakumar, Samuel Seward, Mary E. Bovino, Katherine Xu, Yared Takabe, Fábio E. Amaral, Sumit Mohan, Rebecca Wax, Kaitlyn Corbin, Simone Sanna-Cherchi, Kiyoshi Mori, Lynne Johnson, Thomas Nickolas, Vivette D’Agati, Chyuan-Sheng Lin, Andong Qiu, Qais Al-Awqati, Adam J. Ratner, Jonathan Barasch

×

Figure 1

LCN2 is markedly upregulated in human and mouse UTI.

Options: View larger image (or click on image) Download as PowerPoint
LCN2 is markedly upregulated in human and mouse UTI.
(A) uLCN2 expressio...
(A) uLCN2 expression in LE+Cx+ (100 ng/ml; IQR 30–300 ng/ml; n = 43) versus LE–Cx– patients (14.2 ng/ml; IQR 7.4–35.3 ng/ml; n = 514) in an Emergency Department cohort lacking other forms of kidney disease. (B) Relationship between uLCN2 and uCFU in all LE+ Emergency Department patients (LE+ and <104 uCFU [limit of detection], 45 ng/ml uLCN2, IQR 20–150 ng/ml, n = 75; LE+ and 104–105 uCFU, 250 ng/ml, IQR 40–425 ng/ml, n = 21; LE+ and >105 uCFU, 520.2 ng/ml, IQR 236.7–1,126 ng/ml, n = 45). (C) Suppression of uLCN2 by antibiotics (Pre, 600 ng/ml, IQR 533–700 ng/ml; Post, 83.0 ng/ml, IQR 21–129 ng/ml) in patients presenting to clinic with dysuria, frequency, urgency and LE+ (>30 wbc per high-powered field), hematuria, and mucus threads (n = 4). Values represent median and IQR.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts